Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Models and approaches describing metabolism, transport, and toxicity of drugs administered by the ocular route.

Dumouchel JL, Chemuturi N, Milton MN, Camenisch G, Chastain JE, Walles M, Sasseville V, Gunduz M, Iyer G, Argikar U.

Drug Metab Dispos. 2018 Aug 15. pii: dmd.118.082974. doi: 10.1124/dmd.118.082974. [Epub ahead of print]

PMID:
30111625
2.

Resurrecting Darwin's Niata - anatomical, biomechanical, genetic, and morphometric studies of morphological novelty in cattle.

Veitschegger K, Wilson LAB, Nussberger B, Camenisch G, Keller LF, Wroe S, Sánchez-Villagra MR.

Sci Rep. 2018 Jun 14;8(1):9129. doi: 10.1038/s41598-018-27384-3.

3.

Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.

Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, Peter van Marle S, Legangneux E, Borell H, James AD, Meissner A, Camenisch G, Gardin A.

Drug Metab Dispos. 2018 Jul;46(7):1001-1013. doi: 10.1124/dmd.117.079574. Epub 2018 May 7.

PMID:
29735753
4.

Functional assessment of rat pulmonary flavin-containing monooxygenase activity.

Yilmaz Y, Williams G, Manevski N, Walles M, Krähenbühl S, Camenisch G.

Xenobiotica. 2018 May 15:1-10. doi: 10.1080/00498254.2018.1469804. [Epub ahead of print]

PMID:
29694257
5.

Synthetic biology-based cellular biomedical tattoo for detection of hypercalcemia associated with cancer.

Tastanova A, Folcher M, Müller M, Camenisch G, Ponti A, Horn T, Tikhomirova MS, Fussenegger M.

Sci Transl Med. 2018 Apr 18;10(437). pii: eaap8562. doi: 10.1126/scitranslmed.aap8562.

PMID:
29669854
6.

Evaluation of cAMS for 14C microtracer ADME studies: opportunities to change the current drug development paradigm.

Lozac'h F, Fahrni S, Maria D, Welte C, Bourquin J, Synal HA, Pearson D, Walles M, Camenisch G.

Bioanalysis. 2018 Mar 1;10(5):321-339. doi: 10.4155/bio-2017-0216. Epub 2018 Feb 16.

7.

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.

Jin Y, Borell H, Gardin A, Ufer M, Huth F, Camenisch G.

Eur J Clin Pharmacol. 2018 Apr;74(4):455-464. doi: 10.1007/s00228-017-2404-2. Epub 2017 Dec 22.

8.

Assessment of the pulmonary CYP1A1 metabolism of mavoglurant (AFQ056) in rat.

Yilmaz Y, Umehara K, Williams G, Faller T, Schiller H, Walles M, Kraehenbuehl S, Camenisch G, Manevski N.

Xenobiotica. 2018 Aug;48(8):793-803. doi: 10.1080/00498254.2017.1373311. Epub 2017 Sep 29.

PMID:
28879796
9.

Comparison of 19F NMR and 14C Measurements for the Assessment of ADME of BYL719 (Alpelisib) in Humans.

James AD, Marvalin C, Luneau A, Meissner A, Camenisch G.

Drug Metab Dispos. 2017 Aug;45(8):900-907. doi: 10.1124/dmd.117.075424. Epub 2017 May 31.

10.

Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.

Pearson D, Weiss HM, Jin Y, Jaap van Lier J, Erpenbeck VJ, Glaenzel U, End P, Woessner R, Eggimann F, Camenisch G.

Drug Metab Dispos. 2017 Jul;45(7):817-825. doi: 10.1124/dmd.117.075358. Epub 2017 Apr 25.

11.

Current In Vitro Methods to Determine Hepatic Kpuu: A Comparison of Their Usefulness and Limitations.

Riede J, Camenisch G, Huwyler J, Poller B.

J Pharm Sci. 2017 Sep;106(9):2805-2814. doi: 10.1016/j.xphs.2017.03.025. Epub 2017 Apr 4.

PMID:
28385545
12.

Assessing the Risk of Drug-Induced Cholestasis Using Unbound Intrahepatic Concentrations.

Riede J, Poller B, Huwyler J, Camenisch G.

Drug Metab Dispos. 2017 May;45(5):523-531. doi: 10.1124/dmd.116.074179. Epub 2017 Mar 2.

13.

Pedigree-based inbreeding coefficient explains more variation in fitness than heterozygosity at 160 microsatellites in a wild bird population.

Nietlisbach P, Keller LF, Camenisch G, Guillaume F, Arcese P, Reid JM, Postma E.

Proc Biol Sci. 2017 Mar 15;284(1850). pii: 20162763. doi: 10.1098/rspb.2016.2763.

14.

Bigger Is Fitter? Quantitative Genetic Decomposition of Selection Reveals an Adaptive Evolutionary Decline of Body Mass in a Wild Rodent Population.

Bonnet T, Wandeler P, Camenisch G, Postma E.

PLoS Biol. 2017 Jan 26;15(1):e1002592. doi: 10.1371/journal.pbio.1002592. eCollection 2017 Jan.

15.

Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction.

Njuguna NM, Umehara KI, Huth F, Schiller H, Chibale K, Camenisch G.

Drug Metab Pers Ther. 2016 Dec 1;31(4):221-228. doi: 10.1515/dmpt-2016-0028.

PMID:
27718490
16.

Drug Disposition Classification Systems in Discovery and Development: A Comparative Review of the BDDCS, ECCS and ECCCS Concepts.

Camenisch GP.

Pharm Res. 2016 Nov;33(11):2583-93. doi: 10.1007/s11095-016-2001-6. Epub 2016 Jul 20. Review.

PMID:
27439505
17.

Microsatellite diversity of the Nordic type of goats in relation to breed conservation: how relevant is pure ancestry?

Lenstra JA, Tigchelaar J, Biebach I; Econogene Consortium, Hallsson JH, Kantanen J, Nielsen VH, Pompanon F, Naderi S, Rezaei HR, Saether N, Ertugrul O, Grossen C, Camenisch G, Vos-Loohuis M, van Straten M, de Poel EA, Windig J, Oldenbroek K.

J Anim Breed Genet. 2017 Feb;134(1):78-84. doi: 10.1111/jbg.12226. Epub 2016 Jun 24.

PMID:
27339108
18.

New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data.

Riede J, Poller B, Umehara K, Huwyler J, Camenisch G.

Eur J Pharm Sci. 2016 Apr 30;86:96-102. doi: 10.1016/j.ejps.2016.02.022. Epub 2016 Mar 3.

PMID:
26948853
19.

Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors.

Umehara K, Zollinger M, Kigondu E, Witschi M, Juif C, Huth F, Schiller H, Chibale K, Camenisch G.

Xenobiotica. 2016 Oct;46(10):862-7. doi: 10.3109/00498254.2015.1133867. Epub 2016 Feb 18.

PMID:
26887925
20.

Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.

Kunze A, Poller B, Huwyler J, Camenisch G.

Drug Metab Pers Ther. 2015 Sep;30(3):175-88. doi: 10.1515/dmdi-2015-0003.

PMID:
25996489
21.

A microsatellite-based linkage map for song sparrows (Melospiza melodia).

Nietlisbach P, Camenisch G, Bucher T, Slate J, Keller LF, Postma E.

Mol Ecol Resour. 2015 Nov;15(6):1486-96. doi: 10.1111/1755-0998.12414. Epub 2015 May 1.

PMID:
25865627
22.

Phase II metabolism in human skin: skin explants show full coverage for glucuronidation, sulfation, N-acetylation, catechol methylation, and glutathione conjugation.

Manevski N, Swart P, Balavenkatraman KK, Bertschi B, Camenisch G, Kretz O, Schiller H, Walles M, Ling B, Wettstein R, Schaefer DJ, Itin P, Ashton-Chess J, Pognan F, Wolf A, Litherland K.

Drug Metab Dispos. 2015 Jan;43(1):126-39. doi: 10.1124/dmd.114.060350. Epub 2014 Oct 22.

23.

Aldehyde oxidase activity in fresh human skin.

Manevski N, Balavenkatraman KK, Bertschi B, Swart P, Walles M, Camenisch G, Schiller H, Kretz O, Ling B, Wettstein R, Schaefer DJ, Pognan F, Wolf A, Litherland K.

Drug Metab Dispos. 2014 Dec;42(12):2049-57. doi: 10.1124/dmd.114.060368. Epub 2014 Sep 23.

24.

Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite.

Krauser JA, Jin Y, Walles M, Pfaar U, Sutton J, Wiesmann M, Graf D, Pflimlin-Fritschy V, Wolf T, Camenisch G, Swart P.

Xenobiotica. 2015 Feb;45(2):107-23. doi: 10.3109/00498254.2014.945988. Epub 2014 Sep 2.

PMID:
25180976
25.

Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.

Kunze A, Huwyler J, Camenisch G, Poller B.

Drug Metab Dispos. 2014 Sep;42(9):1514-21. doi: 10.1124/dmd.114.058412. Epub 2014 Jul 2.

26.

In vitro-in vivo extrapolation method to predict human renal clearance of drugs.

Kunze A, Huwyler J, Poller B, Gutmann H, Camenisch G.

J Pharm Sci. 2014 Mar;103(3):994-1001. doi: 10.1002/jps.23851. Epub 2014 Jan 13.

PMID:
24549735
27.

Effect of cimetidine, a model drug for inhibition of the organic cation transport (OCT2/MATE1) in the kidney, on the pharmacokinetics of glycopyrronium.

Dumitras S, Sechaud R, Drollmann A, Pal P, Vaidyanathan S, Camenisch G, Kaiser G.

Int J Clin Pharmacol Ther. 2013 Oct;51(10):771-9. doi: 10.5414/CP201946.

PMID:
24040847
28.

Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.

Kaufmann MR, Schraml P, Hermanns T, Wenger RH, Camenisch G.

Exp Mol Pathol. 2013 Jun;94(3):453-7. doi: 10.1016/j.yexmp.2013.03.005. Epub 2013 Mar 24.

PMID:
23531419
29.

Dysregulation of hypoxia-inducible factor by presenilin/γ-secretase loss-of-function mutations.

Kaufmann MR, Barth S, Konietzko U, Wu B, Egger S, Kunze R, Marti HH, Hick M, Müller U, Camenisch G, Wenger RH.

J Neurosci. 2013 Jan 30;33(5):1915-26. doi: 10.1523/JNEUROSCI.3402-12.2013.

30.

Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-β1 processing.

Wottawa M, Leisering P, Ahlen Mv, Schnelle M, Vogel S, Malz C, Bordoli MR, Camenisch G, Hesse A, Napp J, Alves F, Kristiansen G, Farhat K, Katschinski DM.

Int J Cancer. 2013 Jun 15;132(12):2787-98. doi: 10.1002/ijc.27982. Epub 2012 Dec 27.

31.

Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters.

Kunze A, Huwyler J, Camenisch G, Gutmann H.

Biochem Pharmacol. 2012 Oct 15;84(8):1096-102. doi: 10.1016/j.bcp.2012.07.032. Epub 2012 Aug 4.

PMID:
22902721
32.

The transcription factor encyclopedia.

Yusuf D, Butland SL, Swanson MI, Bolotin E, Ticoll A, Cheung WA, Zhang XY, Dickman CT, Fulton DL, Lim JS, Schnabl JM, Ramos OH, Vasseur-Cognet M, de Leeuw CN, Simpson EM, Ryffel GU, Lam EW, Kist R, Wilson MS, Marco-Ferreres R, Brosens JJ, Beccari LL, Bovolenta P, Benayoun BA, Monteiro LJ, Schwenen HD, Grontved L, Wederell E, Mandrup S, Veitia RA, Chakravarthy H, Hoodless PA, Mancarelli MM, Torbett BE, Banham AH, Reddy SP, Cullum RL, Liedtke M, Tschan MP, Vaz M, Rizzino A, Zannini M, Frietze S, Farnham PJ, Eijkelenboom A, Brown PJ, Laperrière D, Leprince D, de Cristofaro T, Prince KL, Putker M, del Peso L, Camenisch G, Wenger RH, Mikula M, Rozendaal M, Mader S, Ostrowski J, Rhodes SJ, Van Rechem C, Boulay G, Olechnowicz SW, Breslin MB, Lan MS, Nanan KK, Wegner M, Hou J, Mullen RD, Colvin SC, Noy PJ, Webb CF, Witek ME, Ferrell S, Daniel JM, Park J, Waldman SA, Peet DJ, Taggart M, Jayaraman PS, Karrich JJ, Blom B, Vesuna F, O'Geen H, Sun Y, Gronostajski RM, Woodcroft MW, Hough MR, Chen E, Europe-Finner GN, Karolczak-Bayatti M, Bailey J, Hankinson O, Raman V, LeBrun DP, Biswal S, Harvey CJ, DeBruyne JP, Hogenesch JB, Hevner RF, Héligon C, Luo XM, Blank MC, Millen KJ, Sharlin DS, Forrest D, Dahlman-Wright K, Zhao C, Mishima Y, Sinha S, Chakrabarti R, Portales-Casamar E, Sladek FM, Bradley PH, Wasserman WW.

Genome Biol. 2012;13(3):R24. doi: 10.1186/gb-2012-13-3-r24.

33.

Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions.

Camenisch G, Umehara K.

Biopharm Drug Dispos. 2012 May;33(4):179-94. doi: 10.1002/bdd.1784. Epub 2012 Apr 19.

PMID:
22407504
34.

Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat.

Umehara K, Camenisch G.

Pharm Res. 2012 Feb;29(2):603-17. doi: 10.1007/s11095-011-0607-2. Epub 2011 Oct 20.

PMID:
22011931
35.

The putative RNA helicase HELZ promotes cell proliferation, translation initiation and ribosomal protein S6 phosphorylation.

Hasgall PA, Hoogewijs D, Faza MB, Panse VG, Wenger RH, Camenisch G.

PLoS One. 2011;6(7):e22107. doi: 10.1371/journal.pone.0022107. Epub 2011 Jul 13.

36.

Identifying Y-chromosomal diversity by long-template PCR.

Wandeler P, Camenisch G.

Mol Ecol Resour. 2011 Sep;11(5):835-41. doi: 10.1111/j.1755-0998.2011.03013.x. Epub 2011 Apr 1.

PMID:
21457481
37.

Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis.

Bordoli MR, Stiehl DP, Borsig L, Kristiansen G, Hausladen S, Schraml P, Wenger RH, Camenisch G.

Oncogene. 2011 Feb 3;30(5):548-60. doi: 10.1038/onc.2010.433. Epub 2010 Sep 20.

PMID:
20856199
38.

Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation.

Vogel S, Wottawa M, Farhat K, Zieseniss A, Schnelle M, Le-Huu S, von Ahlen M, Malz C, Camenisch G, Katschinski DM.

J Biol Chem. 2010 Oct 29;285(44):33756-63. doi: 10.1074/jbc.M110.132985. Epub 2010 Aug 27.

39.

HIF prolyl-4-hydroxylase interacting proteins: consequences for drug targeting.

Wenger RH, Camenisch G, Stiehl DP, Katschinski DM.

Curr Pharm Des. 2009;15(33):3886-94. Review.

40.

Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.

Balamurugan K, Luu VD, Kaufmann MR, Hofmann VS, Boysen G, Barth S, Bordoli MR, Stiehl DP, Moch H, Schraml P, Wenger RH, Camenisch G.

Oncogene. 2009 Sep 17;28(37):3274-85. doi: 10.1038/onc.2009.186. Epub 2009 Jul 6.

PMID:
19581925
41.

Hypoxia-inducible factor prolyl-4-hydroxylase PHD2 protein abundance depends on integral membrane anchoring of FKBP38.

Barth S, Edlich F, Berchner-Pfannschmidt U, Gneuss S, Jahreis G, Hasgall PA, Fandrey J, Wenger RH, Camenisch G.

J Biol Chem. 2009 Aug 21;284(34):23046-58. doi: 10.1074/jbc.M109.032631. Epub 2009 Jun 22.

42.

Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.

Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP.

J Clin Pharmacol. 2008 Nov;48(11):1323-38. doi: 10.1177/0091270008323258. Epub 2008 Sep 10.

PMID:
18784280
43.

Monitoring of wild birds for Newcastle disease virus in Switzerland using real time RT-PCR.

Camenisch G, Bandli R, Hoop R.

J Wildl Dis. 2008 Jul;44(3):772-6.

44.

ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.

Declèves X, Bihorel S, Debray M, Yousif S, Camenisch G, Scherrmann JM.

Pharmacol Res. 2008 Mar;57(3):214-22. doi: 10.1016/j.phrs.2008.01.006. Epub 2008 Feb 2.

PMID:
18337118
45.

Determination and modulation of prolyl-4-hydroxylase domain oxygen sensor activity.

Wirthner R, Balamurugan K, Stiehl DP, Barth S, Spielmann P, Oehme F, Flamme I, Katschinski DM, Wenger RH, Camenisch G.

Methods Enzymol. 2007;435:43-60.

PMID:
17998048
46.

Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.

Bihorel S, Camenisch G, Lemaire M, Scherrmann JM.

J Neurochem. 2007 Sep;102(6):1749-1757. doi: 10.1111/j.1471-4159.2007.04808.x. Epub 2007 Aug 13.

47.

Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor.

Köditz J, Nesper J, Wottawa M, Stiehl DP, Camenisch G, Franke C, Myllyharju J, Wenger RH, Katschinski DM.

Blood. 2007 Nov 15;110(10):3610-7. Epub 2007 Aug 7.

48.

Regulated function of the prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins.

Nytko KJ, Spielmann P, Camenisch G, Wenger RH, Stiehl DP.

Antioxid Redox Signal. 2007 Sep;9(9):1329-38.

PMID:
17627474
49.

Male germ cell expression of the PAS domain kinase PASKIN and its novel target eukaryotic translation elongation factor eEF1A1.

Eckhardt K, Troger J, Reissmann J, Katschinski DM, Wagner KF, Stengel P, Paasch U, Hunziker P, Borter E, Barth S, Schlafli P, Spielmann P, Stiehl DP, Camenisch G, Wenger RH.

Cell Physiol Biochem. 2007;20(1-4):227-40.

50.

Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.

Bihorel S, Camenisch G, Lemaire M, Scherrmann JM.

Pharm Res. 2007 Sep;24(9):1720-8. Epub 2007 Mar 23.

PMID:
17380257

Supplemental Content

Loading ...
Support Center